Fulgent Genetics (FLGT) announced it has been awarded a five-year contract by the U.S. Department of Veterans Affairs, or VA, to provide hereditary cancer, pharmacogenetic and other genetic testing to Veterans. Fulgent has been periodically providing genetic testing services to the members of the VA since 2017. The award is for up to $99M over five years, including both hereditary cancer testing and pharmacogenetic testing.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio